Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 3/20 | 0.44 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.44 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL5140869 | 0.98 | PER2 (0.43) | PER2CRY1CRY2ALDH1A1MAPT | |
| SCHEMBL6253134 | 0.93 | PER2 (0.41) | PER2CRY1CRY2ALDH1A1MAPT | |
| SCHEMBL29813257 | 0.79 | PER2 (0.40) | PER2CRY1CRY2ALDH1A1MAPT | |
| SCHEMBL27700093 | 0.76 | PER2 (0.34) | PER2CRY1CRY2ALDH1A1ESR1 | |
| SCHEMBL242395 | 0.75 | TSHR (0.42) | PER2CRY1CRY2ALDH1A1HPGD | |
| SCHEMBL28751431 | 0.75 | CYP3A4 (0.38) | PER2CRY1CRY2MAPTNPSR1 | |
| SCHEMBL83497 | 0.74 | TRPM8 (0.40) | PER2CRY1CRY2LMNACYP3A4 | |
| SCHEMBL1374165 | 0.74 | ATM (0.42) | PER2CRY1CRY2ALDH1A1MAPT | |
| SCHEMBL6129999 | 0.73 | APEX1 (0.34) | PER2CRY1CRY2ALDH1A1MAPT | |
| SCHEMBL6253130 | 0.71 | CNR2 (0.43) | ALDH1A1MAPTHPGDHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814669-B2 | Blood sample assay method | Abbott Rapid Diagnostics International Unlimited Company (IE) | 2023-11-14 | — | — | US | disclosed |
| US-20210332410-A1 | BLOOD SAMPLE ASSAY METHOD | Abbott Rapid Diagnostics International Unlimited Company (IE) | 2021-10-28 | — | — | US | disclosed |
| US-11085066-B2 | Blood sample assay method | AXIS-SHIELD AS (NO) | 2021-08-10 | — | — | US | disclosed |
| EP-3473715-B1 | CATALASE INHIBITOR AND METHOD FOR MEASURING ANALYTE USING CATALASE INHIBITOR | PHC HOLDINGS CORP (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-10702503-B2 | Catalase inhibitor and method for measuring analyte using catalase inhibitor | PHC HOLDINGS CORPORATION (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20200131560-A1 | BLOOD SAMPLE ASSAY METHOD | Abbott Rapid Diagnostics International Unlimited Company (IE) | 2020-04-30 | — | — | US | disclosed |
| US-20190321335-A1 | CATALASE INHIBITOR AND METHOD FOR MEASURING ANALYTE USING CATALASE INHIBITOR | PHC HOLDINGS CORPORATION (JP) | 2019-10-24 | — | — | US | disclosed |
| EP-3473715-A1 | CATALASE INHIBITOR AND METHOD FOR MEASURING ANALYTE USING CATALASE INHIBITOR | PHC Holdings Corporation (JP) | 2019-04-24 | — | — | EP | disclosed |
| EP-3435089-A1 | DETERMINATION OF NON-HDL CHOLESTEROL IN BLOOD | Axis-Shield AS (NO) | 2019-01-30 | — | — | EP | disclosed |
| EP-2751575-B1 | BLOOD SAMPLE ASSAY METHOD | AXIS SHIELD AS (NO) | 2018-09-12 | — | — | EP | disclosed |
| US-20170349933-A1 | BLOOD SAMPLE ASSAY METHOD | AXIS-SHIELD AS (NO) | 2017-12-07 | — | — | US | disclosed |
| US-9695464-B2 | Blood sample assay method | AXIS-SHIELD AS (NO) | 2017-07-04 | — | — | US | disclosed |
| US-20140302540-A1 | BLOOD SAMPLE ASSAY METHOD | Abbott Rapid Diagnostics International Unlimited Company (IE) | 2014-10-09 | — | — | US | disclosed |
| EP-2235543-A1 | METHOD TO DETERMINE LIPIDS | Axis-Shield Asa (NO) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009081140-A1 | METHOD TO DETERMINE LIPIDS | AXIS-SHIELD ASA (NO) | 2009-07-02 | — | — | WO | disclosed |
| US-7054514-B2 | Optical waveguide sensor, device, system and method for glucose measurement | KABUSHIKI KAISHA TOSHIBA (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20050147342-A1 | Optical waveguide sensor, device, system and method for glucose measurement | KABUSHIKI KAISHA TOSHIBA (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6903815-B2 | Optical waveguide sensor, device, system and method for glucose measurement | KABUSHIKI KAISHA TOSHIBA (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20030225322-A1 | Optical waveguide sensor, device, system and method for glucose measurement | KABUSHIKI KAISHA TOSHIBA (JP) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702503-B2 | Catalase inhibitor and method for measuring analyte using catalase inhibitor | CAT, MPO, SOD1 | PER2 3082/4885CRY1 1296/4885CRY2 2777/4885 |
| US-20190321335-A1 | CATALASE INHIBITOR AND METHOD FOR MEASURING ANALYTE USING CATALASE INHIBITOR | CAT, MPO, SOD1 | PER2 3082/4885CRY1 1296/4885CRY2 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.